Follow us on Twitter
twitter icon@FreshPatents


Roti patents

      

This page is updated frequently with new Roti-related patent applications.




 System and  plaque serration patent thumbnailSystem and plaque serration
A device and method for intravascular treatment of atherosclerotic plaque prior to balloon angioplasty which microperforates the plaque with small sharp spikes acting as serrations for forming cleavage lines or planes in the plaque. The spikes may also be used to transport medication into the plaque.
Cagent Vascular, Llc


 Compositions and methods of improving performance and intestinal health of poultry patent thumbnailCompositions and methods of improving performance and intestinal health of poultry
Gut health in poultry is improved by providing an efficacious amount of extracts of tannic acid via feed or via drinking water. The extracts of tannic acid are also effective when the poultry are infected with coccidiosis and/or necrotic enteritis.
Kemin Industries, Inc.


 Transdermal delivery system containing rotigotine patent thumbnailTransdermal delivery system containing rotigotine
Transdermal therapeutic system for the transdermal administration of rotigotine containing an therapeutically effective amount of rotigotine base in a self-adhesive layer structure, comprising a) a backing layer, and b) a rotigotine-containing biphasic layer, the bi phasic layer having a) an outer phase having a composition comprising 75% to 100% of a polymer or a polymer mixture, and b) an inner phase having a composition comprising rotigotine base, wherein the inner phase forms dispersed deposits in the outer phase, and wherein the inner phase comprises i. Rotigotine base, and ii.
Ucb Pharma Gmbh


 Compositions and methods that target olfactory receptors for regulation of breathing patent thumbnailCompositions and methods that target olfactory receptors for regulation of breathing
The olfactory receptor olfr78/or51e2 is shown to be expressed in the carotid body and to control breathing responses regulated by acute hypoxia sensing. Activation of olfr78/or51e2 increases breathing, while inhibitors of the receptor can counteract this activity.
The Board Of Trustees Of The Leland Stanford Junio


 Catheter for prevention of stroke and  use patent thumbnailCatheter for prevention of stroke and use
A catheter for prevention of stroke by diverting and filtering the blood flow to carotid and vertebral arteries is provided. The catheter includes at least one balloon with an outer mesh cover that expands upon the balloon inflation and stays expanded after the balloon is deflated.

 Inhibition of gliadin peptides patent thumbnailInhibition of gliadin peptides
Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation


 Devices for controlling magnetic nanoparticles to treat fluid obstructions patent thumbnailDevices for controlling magnetic nanoparticles to treat fluid obstructions
A system for the physical manipulation of free magnetic rotors in a circulatory system using a remotely placed magnetic field-generating stator is provided. In one embodiment, the invention relates to the control of magnetic particles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources.
Pulse Therapeutics, Inc.


 Noninvasive imaging of focal atherosclerotic lesions using fluorescence molecular tomography patent thumbnailNoninvasive imaging of focal atherosclerotic lesions using fluorescence molecular tomography
The present disclosure provides compositions comprising an oligopeptide comprising a fragment of a natriuretic peptide, wherein the fragment comprises the sequence arg-ile-asp-arg-ile (seq id no:1), and a detectable label. Further disclosed are methods of imaging atherosclerotic plaque by optical imaging using a peptide composition..
Washington University


 Methods for producing stable therapeutic formulations in aprotic polar solvents patent thumbnailMethods for producing stable therapeutic formulations in aprotic polar solvents
Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.. .
Xeris Pharmaceuticals, Inc.


 Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators patent thumbnailCompositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
Provided herein are methods of treating, preventing or managing atherosclerosis by administering a pde4 modulator. Pharmaceutical compositions, dosage forms, and kits suitable for use in methods are also provided..
Celgene Corporation


Composition preventing necrotic enteritis in galloanserans

The present invention refers to the use of a glycerol ester composition of at least one short chain fatty acid for preventing and/or alleviating necrotic enteritis in the gastric tract of galloanserans. The glycerol ester composition comprises at least 75% by weight of glyceryl tributyrate, below 25% by weight of glyceryl dibutyrate and below 8% by weight of glyceryl monobutyrate.
Perstorp Ab

Novel compounds as diacylglycerol acyltransferase inhibitors

This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of dgat-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (type 1, type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as myocardial, renal and liver fibrosis, hepatitis c virus infection and acne or other skin disorders.. .
Glaxosmithkline Llc

Delivery of antibodies to the central nervous system

The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptide derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides.
Angiochem Inc.

Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd)

Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd) in humans is disclosed, preferably in hematopoietic stem cell transplantation (hsct), more preferably allogeneic hematopoietic stem cell transplantation. Graft versus host disease of the invention (gvhd) can be acute agvhd and/or chronic cgvhd, preferably acute..
Gentium S.r.l.

Intravascular catheter having an expandable incising portion and medication delivery system

An intravascular device is provided having a catheter tube and an expandable portion including a plurality of struts capable of being moved between an open and a closed position. An incising element is provided on at least one of the struts and has a sharpened edge for creating an incision in atherosclerotic material located within a blood vessel when the expandable portion is in the opened position.

Ultrapure tetrahydrocannabinol-11-oic-acids

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.. .
Corbus Pharmaceuticals, Inc.

Ultrapure tetrahydrocannabinol-11-oic acids

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.. .
Corbus Pharmaceuticals, Inc.

Ultrapure tetrahydrocannabinol-11-oic acids

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.. .
Corbus Pharmaceuticals, Inc.

Microrna treatment of fibrosis

Provided herein are micrornas that target transforming growth factor beta (tgf-β) receptors and attenuate pathways of fibrosis. In particular, microrna-1343 reduces expression of tgfbr1 and tgfbr2, decreases tgf-β signaling, represses pathways of fibrosis, and treats fibrotic diseases..

Polyimide precursor composition and preparing polyimide precursor composition

A polyimide precursor composition includes a mixed solvent and a polyimide precursor dissolved in the mixed solvent, and the mixed solvent contains at least one organic solvent a and at least one organic solvent b, wherein the organic solvent a is selected from the group consisting of an aprotic polar solvent which contains a nitrogen atom and a lactone solvent, and the organic solvent b is selected from the group consisting of a non-aqueous solvent which has a carbonyl structure.. .
Fuji Xerox Co., Ltd.

Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome

The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain dpp-4 inhibitor, as well as to the use of a certain dpp-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.. .
Boehringer Ingelheim International Gmbh

Exclusion of the left atrial appendage

A device for excluding the left atrial appendage (laa) includes first and second members, each with first and second ends. The second ends are connected by a hinge.

High throughput biochemical fluorometric measuring hdl redox activity

In various embodiments, a new, robust fluorometric cell-free biochemical assay that measures hdl redox activity (hra) is provided. In certain embodiments the assay is based on the oxidation of the fluorochrome amplex® red in the presence of hrp.
The Regents Of The University Of California

Aplnr modulators and uses thereof

The present invention provides apelin receptor (aplnr) modulators that bind to aplnr and methods of using the same. The invention includes aplnr modulators such as antibodies, or antigen-binding fragments thereof, that inhibit or attenuate aplnr-mediated signaling.
Regeneron Pharmaceuticals, Inc.

Selectable eccentric remodeling and/or ablation

A catheter and catheter system for eccentric remodeling and/or removal of atherosclerotic material of a blood vessel of a patient include an elongate flexible catheter body with a radially expandable structure. A plurality of electrodes or other electrosurgical energy delivery surfaces can radially engage atherosclerotic material when the structure expands.
Vessix Vascular, Inc.

Electrical ablation devices

An electrical ablation apparatus comprises first and second electrodes. Each electrode comprises a first end configured to couple an energy source and a second end configured to couple to a tissue treatment region.
Ethicon Endo-surgery, Inc.

Methods and devices for transcarotid access

Disclosed is an arterial access sheath for introducing an interventional device into an artery. The arterial access sheath includes an elongated body sized and shaped to be transcervically introduced into a common carotid artery at an access location in the neck and an internal lumen in the elongated body having a proximal opening in a proximal region of the elongated body and a distal opening in a distal region of the elongated body.
Silk Road Medical, Inc.

Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome

The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.
Vanderbilt University

Vascular and intestinal occlusion

A device for occluding a conduit includes first and second members, each with first and second ends. The second ends are connected by a hinge.

Substituted n-(2-(amino)-2oxoethyl)benzamide inhibitors of autotaxin and their preparation and use in the treatment of lpa-dependent or lpa-mediated diseases

The present invention relates to compounds according to formula i and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by atx.. .
X-rx, Inc.

Occluding catheter for prevention of stroke

An occluding catheter for preventing stroke by occluding blood flow through right and left carotid arteries is provided. The occluding catheter includes a shaft that has a proximal end and a distal end, and a proximal occluding balloon carried by the shaft.

Tin-117m somatostatin receptor binding compounds and methods

Tin-117m somatostatin analogues or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic.
Serene, Llc

Treatment of multidrug-resistant nephrotic syndrome (mdr-ns) in children

The present disclosure provides compositions and methods for treating multidrug-resistant nephrotic syndrome (mdr-ns) in pediatric subjects comprising atrasentan. Methods of reducing protenuria in a pediatric patient having mdr-ns are also provided..
Abbvie, Inc.

Cpr patient training mannequin

A cpr patient training mannequin. The cpr patient training mannequin provides for training and teaching individuals in proper cpr technique.

Uses of diazepane derivatives

The present invention provides compounds of formula (ii) (e.g., compounds of formula (i)), and pharmaceutically compositions thereof. Compounds of formula (ii) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (bet) proteins).
Dana-farber Cancer Institute, Inc.

Method for manufacturing 1,1-disubstituted hydrazine compound

This method for a manufacturing a 1,1-disubstituted hydrazine compound represented by a formula (ii) involves reacting a hydrazino compound represented by a formula (i) with a compound represented by a formula: r-hal in an aprotic polar solvent in the presence of a base selected from an alkali metal hydroxide and alkaline-earth metal hydroxide in an amount of 1.0 to 3.0 equivalents based on the hydrazino compound. In the formulae, x represents an oxygen atom, a sulfur atom, —ch2— or the like, and each of rx represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 6 carbon atoms, a cyano group, a nitro group, a fluoroalkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms or the like.
Zeon Corporation

Stable peptide formulations and methods for preparation

Disclosed is a stable formulation for parenteral injection, as well as methods for its use and preparation, that includes a peptide or a salt thereof that has been previously dried from an aqueous composition comprising a partially volatile buffer, a volatile buffer, a strong acid, or a strong base, or any combination thereof, wherein the dried peptide or salt thereof has a first ionization profile that corresponds to the peptide's optimal stability and solubility, and an aprotic polar solvent, wherein the dried peptide or salt thereof is reconstituted into an aprotic polar solvent and has a second ionization profile in the aprotic polar solvent, wherein the first and second ionization profiles are substantially the same, such as within 1 ph unit of one another.. .
Xeris Pharmaceuticals, Inc.

Electrode structures and methods for their use in cardiovascular reflex control

Devices, systems, and methods are described by which the blood pressure, nervous system activity, and neurohormonal activity may be selectively and controllably reduced by activating baroreceptors. A baroreceptor activation device is positioned near a baroreceptor, preferably a baroreceptor located in the carotid sinus.
Cvrx, Inc.

Endovascular implant

A plaque tack can be used for holding plaque against blood vessel walls such as in treating atherosclerotic occlusive disease. The plaque tack can be formed as a thin, annular band for holding loose plaque under a spring or other expansion force against a blood vessel wall.
Intact Vascular, Inc.

Endovascular catheter with multiple capabilities

An endovascular catheter combination configured to have multiple capabilities is disclosed. These capabilities include proximal and distal occlusion of a segment of a target blood vessel (such as the carotid artery) thus excluding the segment of the blood vessel from circulation for purposes such as surgical consideration.
Cosette, Lee & Harrison, Llc





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Roti for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Roti with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.9884

file didn't exist2651

479198 - 0 - 53